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Current statistical prescriptions for low-dosage extrapolation of carcinogenic risk make no dis-
tinction between exposure to initiators and exposure to promoters despite the abundant data that
these two classes of carcinogens have different modes of action. One reason for this is the lack of an
appropriate model. In this paper, a model for carcinogenesis is presented which provides a frame-
work for understanding the roles of "spontaneous" events, hereditary factors, and environmental
agents in human carcinogenesis and for interpreting experimental carcinogenesis. This model incor-
porates two features: transition of target stem cells into cancer cells via an intermediate stage in
two irreversible steps and growth and differentiation of normal target and intermediate cells. Cast
in mathematical terms, the model can be fitted to age-specific incidence data on human cancers of
both children and adults and can illuminate the relative importance of agents that affect transition
rates, tissue growth and tissue differentiation. Within the context of the model, initiators act by af-
fecting the transition rates, whereas promoters influence the kinetics of growth, especially of initi-
ated cells. The model provides a good quantitative description of the epidemiology of carcinomas of
the breast and of the lung. The data are consistent with the notion that hormones and cigarette
smoke act as promoting agents in carcinoma of the breast and of the lung, respectively.
Much attention has been focused on the phenom-
ena of "initiation" and "promotion" in carcinogene-
sis. The fact that agents with such disparate modes
of action-initiators acting at the level of DNA as
mutagens and promoters acting at the cell surface
to cause cell proliferation-can facilitate carcinogen-
esis strongly suggests that both mutations and the
dynamics of tissue growth and differentiation play
important roles in carcinogenesis. The present
paper is predicated on this assumption. I shall pre-
sent a schematic model for carcinogenesis and I
hope to convince you that, in our present state of
knowledge, this model can accomodate much that is
fact about carcinogenesis in animals and humans,
and that it provides a framework for the under-
standing of environmental carcinogenesis in hu-
mans. In addition, the model makes interesting and
testable predictions regarding the clonality of cer-
tain human neoplasms, and suggests new experi-
ments in animals (1).
Evidence from diverse sources suggests that car-
cinogenesis is a multistage process. It is not my in-
tention to review this evidence today, except to
point out that some of the most intriguing evidence
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is derived from human cancers that occur in two
forms: a spontaneous form, and one that is inherited
in an autosomal dominant form on pedigree analy-
sis. In such cancers inheritance of the gene in-
creases enormously the risk of getting cancer. How-
ever, even though all the cells of the affected organ
carry the gene, only a few tumors arise, suggesting
that inheritance of the gene is not sufficient and
that at least one other event is necessary for malig-
nant transformation. An attractive hypothesis is
that only one other event is necessary for malignant
transformation: a two-stage model for malignant
transformation is consistent with the development
of homozygosity at a cancer gene locus.
I would like to present a two-stage model for car-
cinogenesis and deduce some of its consequences.
There is strong evidence that the first critical event
in carcinogenesis is a mutation: unfortunately, there
is much less information on the nature of the subse-
quent events. Nevertheless, lurking in the back-
ground, behind the model, is the notion that both
the critical events are mutations, probably at the
same site on homologous chromosomes. Specifically,
a genetic regulatory schema proposed by Comings
(2) is attractive. Comings suggests that all cells con-
tain oncogenes capable of coding for transforming
factors that can release the cell from normal growthS. H. MOOLGAVKAR
constraints. These oncogenes, which are tissue-spe-
cific, are temporarily expressed during embryogen-
esis but are turned off by diploid pairs of regulatory
genes. According to a two-event model then, most
human malignant tumors arise when both regula-
tory genes in a diploid pair sustain mutations, thus
releasing the oncogenes from control. Of course, the
possibility that oncogenes may be turned back on in
other ways must be admitted. For example, chromo-
somal rearrangement to bring an oncogene adjacent
to a "promoter" site may do this. Insertion of a viral
promoting sequence next to an oncogene would
have the same effect. The word promoter here is
not to be confused with promotion in chemical carci-
nogenesis. It is unfortunate that the same word is
used in a technical sense in both molecular genetics
and chemical carcinogenesis. Figure 1 is a schematic
representation of the model.
Initiation and Promotion
In chemical carcinogenesis, the words "initiation"
and "promotion" have hitherto been used phenome-
nologically: a promoter is a substance which when
applied after (but not before) an initiator gives rise
to tumors. Thus, these notions, strictly speaking,
have meaning only in the context of animal experi-
ments. However, they have been picked up and
IL
First Event Second Event
FIGURE 1. Two-stage model for carcinogenesis. S = normal
stem cell, I = intermediate (one-hit) cell, D = dif-
ferentiated (or dead) cell, M = malignant cell; yA = rate at
which first event occurs, P2
= rate at which second event
occurs, a2 = rate of division of intermediate cells, P2 =
rate of differentiation and death of intermediate cells. In a
small time interval, a given stem cell (S) may divide with a
certain probability to give rise to two daughter cells (S), or
it may differentiate (or die) (D) and thus leave the pool of
susceptible cells, or it may divide (with a small probability)
into two cells one of which is normal (S) and the other of
which has suffered the first event to become an in-
termediate cell (I). The intermediate cell may in turn give
rise to two intermediate daughters (I); die or differentiate
(D); or give rise (with a small probability) to one in-
termediate cell (I) and one malignant cell (M).
used rather loosely by scientists in other disciplines.
Within the context of the model presented above,
the words "initiator" and "promoter" can be given
precise meaning. An initiator is any agent that in-
creases,u the probability of transition from a nor-
mal stem cell to a once-hit intermediate cell. A pro-
moter is an agent that acts on intermediate cells to
increase a2, decrease f2' or both. This results in a
proliferation of intermediate cells to give rise to in-
termediate lesions. The papillomas that arise in the
now-classical skin-painting experiments and the
enzyme-altered foci that have been described in
AAF-induced rat hepatocarcinogenesis can be con-
sidered to be examples of such intermediate lesions.
Thus, promoters act on cells that have sustained a
single critical event to cause their proliferation, i.e.,
they act as selective mitogens. This proliferation
leads to an enormous increase in the number of in-
termediate cells, and thus increases the probability
that one of these cells will sustain the second criti-
cal event and become malignant. Such a scenario
has been proposed independently by Potter (3) for
hepatocarcinogenesis in rats and suggests that an
experiment in which application of an initiator is fol-
lowed by several applications of promoter until in-
termediate lesions appear and then by another ap-
plication of initiator should yield a larger number of
malignant tumors than initiation-promotion alone
(which should yield mainly intermediate lesions).
The model for initiation-promotion presented above
raises some fundamental questions. If both critical
events in carcinogenesis are mutations, can there be
agents that could be classified as "pure" initiators?
Prolonged application of an initiator (a mutagen)
should lead eventually to the development of true
malignancies. If the initiator has some promoting ac-
tivity, one should see both intermediate lesions
(such as the papillomas) and true malignant lesions.
In fact, it is known from the classical skin painting
experiments, that a regimen of initiation-promotion
leads to a large number of papillomas (intermediate
lesions) and a few malignant lesions. On the other
hand, prolonged application of initiators leads to the
appearance of mainly malignant tumors (4). Thus a
pure initiator would seem to be a mythical beast. To
my knowledge, there is only one agent that has
been labeled a pure initiator in the literature: ure-
thane (5). However, the studies that conclude that
urethane is a pure initiator are far from convincing:
they were not carried out for long enough or with
large enough populations of animals to rule out the
eventual appearance of malignant tumors. All that
one can conclude from these experiments is that re-
peated applications of urethane to mouse skin do
not seem to produce papillomas.
If the two critical mutations in carcinogenesis oc-
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cur at the same site on homologous chromosomes,
an intriguing possibility arises. There could be
agents that are not promoters in the sense defined
above but still increase the probability of the second
event without affecting the first. Homozygosity at
the critical site could be brought about not only by
mutations but by homologous chromosome ex-
change during mitosis. Any agent that favors mi-
totic recombination could act in this way. Thus,
within the context of the model, in addition to initia-
tors and promoters, it is possible to postulate the
existence of a third class of agents that facilitate
carcinogenesis. Perhaps these hypothetical agents
should be called completers. As I shall point out
later, there is at least one genetic condition in hu-
mans that seems to predispose to cancer in this
way. Of course, as has been noted above, agents
may act in more than one way to facilitate tumori-
genesis. Thus, many initiators have some promoting
activity, and it has been suggested that the phorbol
esters may facilitate mitotic recombination and thus
have "completer" activity (6).
Genetic Predisposition to Cancer
Thus, within the framework of the model, envi-
ronmental agents and genetic predisposition to can-
cer could, broadly speaking, facilitate carcinogenesis
in one of two ways: by increasing the transition
rates ,u, or j2 or both or by increasing the prolifera-
tion of normal or intermediate cells. I shall come
back to the implications of this for environmental
carcinogenesis shortly. I want to point out first that
there are genetic conditions in humans that predis-
pose to cancer in each of these ways. Perhaps the
most important examples of genetic predisposition
in humans are provided by those cancers that, on
segregation analysis, are inherited in an autosomal
dominant fashion. Examples are hereditary retino-
blastoma and carcinoma of the colon in familial
polyposis. According to the model, affected individu-
als have inherited the first event and are born with
the cells of the affected tissue in the intermediate
stage (7). Then, there are recessive conditions such
as xeroderma pigmentosum, in which there is defec-
tive repair of ultraviolet-induced DNA damage.
Such a condition would simply increase the proba-
bility of mutations thus increasing both p, and 2. In
one recessive condition, Bloom's syndrome, there is
a great increase in sister chromatid and homologous
chromosome exchanges. As discussed earlier, this
would lead to an increase in p2 without an increase
in p,u. A possible example of a genetic condition that
affects the kinetics of normal tissue leading to an in-
creased susceptibility to cancer is provided by Fan-
coni's anemia, an autosomal recessive condition. The
kinetics of bone marrow cells are severely dis-
turbed in individuals with this disease, and afflicted
individuals are at increased risk of leukemia. There
is no evidence that DNA repair is deficient in indi-
viduals with Fanconi's anemia (8).
Age-Specific Incidence in Human
Populations
I would like to turn my attention now to some
aspects of the epidemiology of human cancers. First,
the two-stage model presented above can be cast in-
to mathematical form to yield an expression for the
age-specific incidence rate of cancer of a specific
site. The age-specific incidence rate per 100,000 in-
dividuals in the population is given by I(t) x 105,
where
I(t)PO
- P 2 fotX(S){(a2 - P2) (t - s)}ds (1)
Here pi and p2 are the transition rates per cell per
year, and X(s) represents the number of normal sus-
ceptible cells at time (age) s (1,9). This expression for
age-specific incidence is not as simple as that de-
rived from the Armitage and Doll (10) model. How-
ever, it should be noted that the growth of normal
and intermediate cells enters explicitly into the
equation. It should also be noted that (1) the transi-
tion rates A,u andp2 are multiplicative factors and are
important in determining the overall incidence rates
of the cancer in question; however, they do not in-
fluence the shape of the incidence curve; and (2) the
shape of the incidence curve is strongly influenced
by the growth curve of the normal tissue and the
cellular kinetics of intermediate cells. Moreover, it
is the difference between "birth rate" and "death
rate," i.e., a2 - P2' that affects incidence, not the in-
dividual parameters. The expression (1) for age-spe-
cific incidence rate applies only when 1A,,129 2 and P2
remain constant. If these parameters change in re-
sponse to changes in environment, then appropriate
changes must be made in the expression for I(t).
However, it is fair to say that initiators (mutagens)
which affect pi andp2, have a much smaller effect on
the shape of the incidence curve than promoters,
which affect a2 - P2. I would like to note also that,
unlike the Armitage-Doll model which generates the
age-specific incidence curves only of many adult car-
cinomas, the two-stage model described here gener-
ates the age-specific incidence curves of childhood
tumors and exceptional tumors such as breast can-
cer in females as well (1,9,11). Moreover, the model
shows that the shape of the age-specific incidence
curve of cancer of a specific tissue is dependent
upon the kinetics of growth and differentiation of
that tissue, a biologically appealing result.
It is known that many human cancers have age-
specific incidence curves with characteristic shapes
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that are similar in various populations, even though
the rates of these cancers may vary enormously
(12,13). Thus, within the framework of the model,
the international variation in rates is due to differ-
ences in p, or p2 or both. An obvious exception is
lung cancer in which the promotional effect of ciga-
rette smoke is probably important. This is discussed
later.
Action of Environmental Agents
Let me turn my attention now to the action of en-
vironmental agents. I shall restrict my discussion to
chronic exposure. The implications of the model for
short-term high intensity exposure to agents such
as radiation has been discussed in a recent publica-
tion (1). In environmental carcinogenesis, we need to
consider not only the consequences of chronic expo-
sure to agents, but also the consequences of discon-
tinuing exposure to these agents. For simplicity, I
shall only discuss the case in which exposure begins
at birth. Exposure beginning later in life yields es-
sentially the same conclusions. Suppose that an
agent acts directly on the transition rates and that
exposure to such an agent starts at time 0. Then
the expression for the age-specific incidence rates
shows that the risk in persons exposed to a given
dose relative to nonexposed individuals remains
constant with time (regardless of whether the first
or the second transition rate is affected) provided
that exposure to that dose increases the transition
rates to new constant levels. On the other hand, if
an agent increases the proliferation of intermediate
cells by a constant amount (i.e., increases a2 - P2
without affecting transition rates), then the risk in
persons exposed relative to those not exposed in-
creases with time. Thus, within the context of the
model, if an agent (promoter), affects the kinetics of
intermediate cells, then duration of exposure to this
agent is an effect modifier in standard epidemiologic
CO)
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FIGURE 2. Relative risk (a) as a function of time when chronic
exposure to an agent (from time 0) increases u, or 12 (or
both) to a new constant level and (b) as a function of time
when chronic exposure to an agent increases a2
- P2.
parlance (Fig. 2). This is because the ratio of the
number of intermediate cells in exposed individuals
to that in nonexposed individuals increases with
time. This ratio remains constant with time when
the agent affects transition rates alone. The model
also predicts that promoting agents are remarkably
efficient in affecting incidence: small changes in
a2-(32 lead to large changes in incidence. Small
changes in the growth kinetics of normal cells have
little effect on incidence. However, in some in-
stances the changes may be large enough to affect
cancer incidence. Thus, nonspecific stimuli for cell
proliferation such as chronic irritation may act in
this fashion.
Suppose now that chronic exposure to an envi-
ronmental agent is stopped. If an agent affects only
the first transition rate, then stoppage of exposure
leads to an incidence curve that lies in between the
incidence curves in exposed and nonexposed indi-
viduals. In other words, even after exposure is
stopped, the incidence rate never goes back to pre-
exposure levels. The reason for this is intuitively
clear: during exposure, there is a build-up of cells in
the intermediate compartment. On the other hand,
if the agent affects the second transition rate alone,
discontinuance of the exposure leads to a quick re-
version of the incidence rate to pre-exposure levels.
TIME
(a)
(b) (c)
FIGURE 3. Effect of stopping chronic exposure to en-
vironmental agents: (a) exposure to an agent that increases
j, (initiator); (b) exposure to an agent that increases M2; (c)
exposure to an agent that increases a2 - P2 (promoter). In
all three figures, (1) is the incidence curve in the exposed
population, (2) is the incidence curve in the unexposed
population and (3) is the incidence curve after exposure is
stopped at the time indicated by the arrow.
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Finally, if exposure to a promoter is discontinued,
the incidence rates will again lie between the inci-
dence curves among exposed and nonexposed indi-
viduals (Fig. 3).
Epidemiology of Lung and Breast
Cancer
Doll (14) has constructed an age-specific incidence
curve for lung cancer in nonsmokers. Although this
curve is based on a small number of age groups, it
seems likely that the age-specific incidence rates in
nonsmokers increases with about the fourth power
of age. As can be seen from Figure 4, the model pro-
vides an excellent description of the data. With re-
gard to the influence of cigarette smoke, various
studies (15,16) suggest that for a given daily level of
smoking, the relative risk increases with duration of
smoking. That is, duration of smoking is an effect
modifier. In addition, data are now becoming avail-
able on smokers who quit. These data indicate that
the risk in exsmokers has not reverted to the risk
in the nonsmoking population in 15 years. However,
the sharp increase in risk seen in continuing
smokers is averted. Thus, the minimal hypothesis
that is consistent with all the facts is that cigarette
smoke increases the proliferation of the intermedi-
ate cells, i.e., acts as a promoter. Indeed there is evi-
dence that cigarette smoke causes hyperplasia of
the bronchial epithelium (17) and is known to con-
tain tumor promoters (18). Thus, even though ciga-
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FIGURE 4. Fit of the model to age-specific incidence data on
carcinoma of the lung in nonsmokers. From Moolgavkar
and Knudson, (1).
rette smoke contains mutagens and would, there-
fore, be expected to increase the transition rates to
some extent, the most important effect of smoke
would seem to be promotion.
I would now like to discuss another example from
human epidemiology. Breast cancer in females is a
most interesting tumor in that it has a peculiar age-
specific incidence curve and age at first full-term
pregnancy is a well recognized risk factor. If the
age-specific incidence of breast cancer is observed
during a single time period, two distinct patterns
emerge. In Western populations, in which risks are
high and more or less stable, the age-specific inci-
dence rates rise till about menopause, level off and
then continue to rise though less steeply than be-
fore menopause. In Eastern populations, exempli-
fied by the prefecture of Osaka in Japan, in which
risks are low and increasing, the age-specific inci-
dence curve rises till menopause, levels off and then
shows an actual fall. However, this fall in rates in
cross-sectional data is due to the cohortwise in-
crease in risks in Osaka. After adjustment for co-
hort effects, the age-specific incidence curve contin-
ues to rise after menopause as it does in the West
(13). Thus, the shapes of the age-specific incidence
curves of female breast cancer are identical in East-
ern and Western populations: it is the magnitude of
the rates that sets these populations apart.
When the physiological responses of the breast
tissue to menarche and menopause are incorporated
into the two-stage model it generates an age-specific
incidence curve that describes well the shape of the
age-specific incidence curve of female breast cancer
(Fig. 5). The cellular transition rates M, and IA2 deter-
mine the magnitude of the incidence rates in a popu-
lation, and adjustment of the transition rates then
generates curves that are in close quantitative
agreement with those observed in six test popula-
tions: Connecticut, Denmark, Finland, Slovenia, Ice-
land, and Osaka (11). According to the model, hor-
mones influence the epidemiology of breast cancer
in females by their actions on the kinetics of growth
of nonneoplastic (normal and intermediate cells)
breast tissue. The breast grows in response to hor-
monal stimuli at puberty, and it involutes when
these stimuli are removed at menopause. It is these
two major kinetic changes imposed on the breast by
hormonal influences that, according to the two-stage
model, determine the basic shape of the age-specific
incidence curve of carcinoma of the breast.
A full-term pregnancy is assumed to cause a cer-
tain fraction of normal and intermediate cells to un-
dergo differentiation and thus remove this fraction
from the population of susceptible cells. Experimen-
tal evidence that such a mechanism operates in rat
mammary glands has recently been obtained by
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FIGURE 5. Fit of the model to age-specific breast cancer
incidence data from various populations. All curves have
been normalized so that the sum of the rates over all age
groups is the same. From Moolgavkar et al. (11).
Russo and Russo (19). With this assumption, the
model predicts a protective effect of an early first-
birth that is in good agreement with data from a
multinational study (Fig. 6) (11). Full-term pregnan-
cies after the first could also stimulate differentia-
tion and further decrease risk, and indeed, a recent
prospective study in Iceland concluded that full-
term pregnancies after the first decreased risk.
Thus, in our view, the features of the epidemiology
of breast cancer that indicate that risk is mediated
hormonally arise from the hormonal effect on tissue
kinetics. Since both the age-specific incidence curve
and the first-birth effects, which are strongly depen-
dent on tissue kinetics, are similar in populations
with different levels of risk, one might infer that
the cell kinetics of breast tissue and hormone levels
are similar in the different populations. The studies
that have reported no noteworthy differences in
hormone levels between low-risk and high-risk pop-
ulations are consistent with this viewpoint.
Finally, the model provides a logical explanation
* OBSERVED RISK ESTIMATES
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FIGURE 6. Risk of breast cancer for different ages at first
full-term pregnancy relative to first full-term pregnancy at
age 20 compared with predictions from the model. From
Moolgavkar et al. (11).
of genetic predisposition to breast cancer and of
breast cancer in irradiated women. These issues are
dealt with in detail in Moolgavkar et al. (11.)
To summarize, I have presented a biologically
based two-stage model for carcinogenesis. Ac-
cording to this model, carcinogenesis is the result of
two critical events, probably mutations. Initiation,
i.e., acquisition of the first event leads to an improp-
erly controlled proliferation of cells that have sus-
tained this event. It is on these intermediate, or
first stage, cells that promoters act as selective mi-
togens. Thus, the two stages in the model refer to
the occurrence of the two critical events. Promotion
is not a stage; rather promoters act on cells in the
first stage to cause their expansion into clones. Hu-
man epidemiologic data are consistent with the
view that estrogens act as promoters in female
breast cancer, and that cigarette smoke acts as a
promoter in lung cancer. The model is consistent
with facts both from human epidemiology and from
animal experiments. In view of the different modes
of action of initiators and promoters, it is clear that
single statistical prescriptions for extrapolation of
risk to low doses cannot possibly apply in all situa-
tions. Sensible extrapolations can be made only
when the mode of action of the specific agent under
study is known.
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